Comparative Pharmacology
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus TORECAN.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE versus TORECAN.
PHENYLEPHRINE HYDROCHLORIDE AND PROMETHAZINE HYDROCHLORIDE vs TORECAN
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenylephrine is a selective alpha-1 adrenergic receptor agonist causing vasoconstriction; promethazine is a phenothiazine derivative that blocks histamine H1 receptors and has anticholinergic, antiemetic, and sedative effects.
TORECAN (thiethylperazine) is a phenothiazine derivative that acts primarily as a dopamine D2 receptor antagonist in the chemoreceptor trigger zone (CTZ) to exert antiemetic effects. It also possesses anticholinergic and antihistaminergic properties.
IV: 0.1-0.5 mg phenylephrine and 12.5-25 mg promethazine as a single dose.
10 mg orally or intramuscularly every 6 to 8 hours as needed for nausea and vomiting.
None Documented
None Documented
Phenylephrine: 2-3 hours (terminal). Promethazine: 10-14 hours (terminal in adults; prolonged in elderly and hepatic impairment).
Terminal elimination half-life: 6-8 hours. Clinical context: Allows twice-daily dosing; prolonged in renal impairment.
Phenylephrine: renal (80% as unchanged drug and sulfate conjugates). Promethazine: renal (70-80% as metabolites and unchanged drug), fecal (20-30%).
Primarily renal (60-70% as unchanged drug and metabolites); biliary/fecal (20-30%).
Category A/B
Category C
Antihistamine / Antiemetic
Antiemetic